Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1389 | Group 2: control group with enoxaparin 40mg/d Wiki | 0.58 |
drug3927 | measurement of circulating sFlt1 concentration Wiki | 0.58 |
drug2630 | Premier Biotech COVID-19 IgG/IgM Rapid test Cassette Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D018352 | Coronavirus Infections NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 3 clinical trials
This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).
Description: Oropharangeal swabs
Measure: Change in respiratory viral clearance (by PCR) Time: Days 3 and 10Description: Fecal swabs
Measure: Fecal viral clearance (by PCR) Time: Day 14Description: Oropharngeal swabs
Measure: Reduction (change) in respiratory viral shedding (by PCR) Time: Days 1,3,7,10,14Description: Fecal swabs
Measure: Reduction (change) in GI viral shedding (by PCR) Time: Days 1,3,7,10,14, 21Description: Defined as 1) O2 saturation <92% on room air (in two consecutive measurements at least 2 hours apart) OR 2) requirement of hospitalization OR 3) need for artificial ventilation OR 4) death.
Measure: Progression to severe COVID-19 Disease Time: Enrollment through final day of participationDescription: Days
Measure: Time to resolution of a fever Time: Enrollment through final day of participationDescription: Composite counts by Adverse Events and Serious Adverse Events
Measure: Incidence of Adverse Events (AEs) Time: Enrollment through 30 days after final day of participationStudy of ANA001 in Moderate COVID-19 Patients
Description: Incidence of treatment emergent adverse events (TEAE's)
Measure: Safety and Tolerability of ANA001 as measured by the incidence of treatment emergent adverse events (TEAE's) (Part 1 and Part 2) Time: Randomization to Day 28Description: Median time to hospital discharge
Measure: Efficacy as measured by median time to hospital discharge (Part 2) Time: Randomization to Day 60Description: Median time to hospital discharge
Measure: Efficacy as measured by median time to hospital discharge (Part 1) Time: Randomization to Day 60Description: Plasma concentrations of ANA001
Measure: Pharmacokinetics (PK) of ANA001 as measured by plasma concentrations (Part 1) Time: Day 1, 2, 3 or 4Description: Mean change from baseline in National Early Warning Score (NEWS 2) score
Measure: Efficacy of ANA001 as measured by mean change from baseline in the National Early Warning Score (NEWS 2) (Part 2) Time: Day 8, Day 15Description: Mean number of days on rescue therapy
Measure: Efficacy of ANA001 as measured by mean number of days on rescue therapy (Part 2) Time: Within 15 days after enrollmentNiclosamide is a well-established substance that is a promising candidate for a repurposing approach to treat COVID-19. Niclosamide is currently marketed as a chewing tablet for the treatment of intestinal worm infections. The marketed formulation is optimized for minimal drug substance absorption. A niclosamide solution has been developed that is expected to release the drug substance more readily and more reproducibly. Camostat is approved for oral treatment of chronic pancreatitis and reflux oesophagitis in Japan. Camostat has been shown to effectively block viral replication in a SARS-CoV-2 animal model. Since the mechanisms of actions are different, it was hypothesized that a combination of both substances might have an additive or even synergistic effect in the treatment of COVID-19 patients. This 3-part study is designed to investigate (1) safety and pharmacokinetics of single ascending doses of the new niclosamide solution after fasted and fed conditions, (2) the relative bioavailability of the niclosamide solution compared to the chewing tablet, and (3) safety and pharmacokinetics of the combination of niclosamide solution and camostat after multiple doses in healthy volunteers.
Description: Assessment of severity of an AE will be based on CTCAE Version 5.0
Measure: Treatment emergent number of Adverse Events Time: up to 14 daysDescription: Measurement will start at Day 1
Measure: Maximum plasma concentration of niclosamide (µg/ml) Time: from predose until 24 hours after interventionDescription: Measurement will start at Day 1
Measure: Area Under the Plasma Concentration Time Curve from predose until last detectable concentration of niclosamide(AUC0-last) of niclosamide [µg/ml*h] Time: from predose until 24 hours after interventionDescription: Measurement will start at Day 1 after a standard high fat breakfast
Measure: Food effect on maximum plasma concentration of niclosamide (µg/ml) Time: from predose until 24 hours after interventionDescription: Measurement will start at Day 1 after a standard high fat breakfast
Measure: Food effect on Area Under the Plasma Concentration Time Curve from predose until last detectable concentration of niclosamide (AUC0-last) [µg/ml*h] Time: from predose until 24 hours after interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports